Free tool
FAERS Monitor: Tham
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 013025 or its brand name (Tham, Tromethamine, Potassium Chloride, Sodium Chloride). Reports on generic versions are filed under their own applications.
Reports
179
Serious
109
61% of reports
Hospitalization
57
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea23
- urinary tract infection22
- drug ineffective18
- headache18
- pain17
- fall16
- off label use16
- vomiting15
- diarrhoea14
- fatigue14
- drug interaction11
- product dose omission issue11
- pyrexia10
- sinusitis10
- chronic obstructive pulmonary disease9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 12 |
| 2018 | 8 |
| 2019 | 13 |
| 2020 | 26 |
| 2021 | 13 |
| 2022 | 12 |
| 2023 | 25 |
| 2024 | 17 |
| 2025 | 17 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,980 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic obstructive pulmonary diseaseSignal | 9 | 20.3 | 10.7 | 147 |
| urinary tract infectionSignal | 22 | 15.2 | 10.2 | 279 |
| sinusitisSignal | 10 | 11.5 | 6.3 | 86 |
| drug interactionSignal | 11 | 8.1 | 4.6 | 62 |
| fallSignal | 16 | 5.6 | 3.5 | 58 |
| product dose omission issueSignal | 11 | 4.4 | 2.5 | 26 |
| vomitingSignal | 15 | 3.7 | 2.3 | 28 |
| nauseaSignal | 23 | 3.4 | 2.3 | 38 |
| pyrexiaSignal | 10 | 3.4 | 1.9 | 15 |
| headacheSignal | 18 | 3.4 | 2.2 | 29 |
| painSignal | 17 | 3.3 | 2.1 | 25 |
| diarrhoeaSignal | 14 | 2.5 | 1.5 | 12 |
| off label useSignal | 16 | 2.1 | 1.3 | 9 |
| fatigueSignal | 14 | 2.1 | 1.3 | 7 |
| drug ineffective | 18 | 1.6 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.